Codis, a newly established contract development and manufacturing organization (CDMO), has entered the pharmaceutical outsourcing market with a focus on commercial-scale spray drying and amorphous solid dispersion technologies. The company announced its official launch this week, positioning itself to support drug developers in improving the bioavailability of poorly soluble active pharmaceutical ingredients (APIs).
With facilities designed for large-scale production, Codis aims to provide end-to-end support, from formulation development through commercial manufacturing. Spray drying has gained prominence in the industry as a method to convert crystalline drugs into amorphous forms, enhancing dissolution rates and enabling effective delivery of challenging compounds. Amorphous solid dispersions, often produced via spray drying, continue to be a critical technology for addressing formulation barriers encountered in oral solid dosage forms.
Codis leadership highlighted that its platform targets pharmaceutical and biotechnology companies seeking reliable outsourcing partners for both clinical and commercial phases. The CDMO’s integrated service model includes process optimization, scale-up expertise, and regulatory support for global market submissions.
Industry analysts note that demand for specialized CDMOs with spray drying capabilities is expected to rise in the coming years, driven by trends in small molecule drug development and the need for solubility enhancement technologies. Codis’s market entry reflects ongoing growth in outsourced pharmaceutical manufacturing, as companies look for partners with deep technical capabilities in niche drug delivery methods.
The company’s launch aligns with increasing commercialization of APIs requiring novel formulation approaches, potentially adding competitive capacity to a rapidly evolving segment of the CDMO sector.